9:00 p.m. – 9:05 p.m. Introduction 8:05 a.m. – 8:10 a.m. 9:05 p.m. – 9:10 p.m. Delivering an Innovative Pipeline to Our Patients: Spotlight on Select Wave 1 Programs Andy Plump, president of Research and Development 8:10 a.m. – 8:35 a.m. 9:10 p.m. – 9:35 p.m. Maribavir (TAK-620): Potential Game Changer in the Treatment for Post-Transplant Cytomegalovirus (CMV) Infection Obi Umeh, global program lead, Rare Genetic and Hematology Therapeutic Area Unit Claus Jepsen, head of Global Product and Launch Strategy, Rare Genetic and Hematology Therapeutic Area Unit 8:35 a.m. – 8:40a.m. 9:35 p.m. – 9:40p.m. Break 9:40 p.m. – 10:00 p.m. Soticlestat (TAK-935): Novel MoA for Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome